about
Determination of the P1', P2' and P3' subsite-specificity of factor Xa.Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells.Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans.Inherited factor VII deficiency: identification of two novel mutations (A191V and T239P) in the catalytic domain.Ticagrelor reversal: in vitro assessment of four haemostatic agents.The gamma-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding.Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide.Protein C activation.Contribution of interactions with the core domain of hirudin to the stability of its complex with thrombin.The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulinPulsed cavitational therapy using high-frequency ultrasound for the treatment of deep vein thrombosis in an in vitro model of human blood clot.Gestational age-related patterns of AMOT methylation are revealed in preterm infant endothelial progenitors.Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates.Characterization of the specificity of arginine-specific gingipains from Porphyromonas gingivalis reveals active site differences between different forms of the enzymes.[The VKOR target for warfarin identified].Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions.Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression.Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin.Glu192-->Gln substitution in thrombin yields an enzyme that is effectively inhibited by bovine pancreatic trypsin inhibitor and tissue factor pathway inhibitor.Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxabanMultimodal assessment of non-specific hemostatic agents for apixaban reversalThrombin Glu-39 restricts the P'3 specificity to nonacidic residuesThe role of calcium ions in factor X activation by thrombin E192QProteolytic derivatives of thrombinFunctional identification of t-PA in crude and purified systemsThe role of thrombin's Tyr-Pro-Pro-Trp motif in the interaction with fibrinogen, thrombomodulin, protein C, antithrombin III, and the Kunitz inhibitorsThe response to thrombin of human neutrophils: evidence for two novel receptorsCharacterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesisRole of the P2 residue in determining the specificity of serpinsIdentification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsinMapping of the thrombin des-ETW conformation by using site-directed mutants of hirudin. Evidence for the induction of nonlocal modifications by mutagenesisInhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the proteaseThe dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1The role of Glu(192) in the allosteric control of the S(2)' and S(3)' subsites of thrombinIntrinsic specificity of the reactive site loop of alpha1-antitrypsin, alpha1-antichymotrypsin, antithrombin III, and protease nexin IElectrostatic steering and ionic tethering in the formation of thrombin-hirudin complexes: the role of the thrombin anion-binding exosite-I
P50
Q30874190-BF303572-7104-4B67-9A7E-02C200D7B3EAQ35458444-B9A34A6A-FBE6-47FA-8A7C-E00B7860A98BQ36263562-39709961-3101-49F2-B51E-3D557ACA5EA6Q38915017-FC54E8CF-0526-46A5-A0C8-BF285496D5F2Q38979976-3C4BCA86-3E3A-44B5-BA5D-F69EACC4D03CQ40526051-1A3D13CF-4F9E-4385-81BE-61370BE9BA22Q40749760-4D56F8D6-B10C-4D0B-9ADB-2E9EED9EC58EQ41582235-86111FAC-8575-4517-83F2-674830D1FF0AQ41822713-86CD7907-43B3-4AD0-BB99-1FAB99AE793AQ42619428-744DD5AF-BA65-4B1C-B2CA-466E3D2CE98AQ42695738-3691F371-AB45-4799-A50D-836A87DDDC31Q42696297-08AA2F99-D76C-498F-A80B-6DD8242003A2Q43941686-48C6A92E-3FD7-4972-A631-E14A5CB4FCBBQ44608196-D775DAD1-7EDF-4AF1-90DE-59CC716E37A9Q44931551-F9837EFA-54C4-4867-9305-B950D27DAC97Q45331644-2E642CF5-81D2-47F3-A3E5-1C96522ABC59Q45887421-D14B0FB5-275B-4679-ACB7-DE43EB7F9590Q47418397-CB01245D-817B-4FDD-859F-D0891466708FQ47445041-F293DFA8-D75C-41D7-9265-AC6A0624E485Q48217958-ED771CC9-245A-44C2-8A00-2A384B7D91ADQ49865391-EA575E38-C8B7-4933-ACBA-7B78470C9B6DQ53589389-ACB4691B-310F-4C98-B9BA-919A00CF7C37Q54199473-375E0FA7-AE6B-449F-87F2-F39EEE01B88FQ59268533-E9DD90A1-C881-4B74-8F2F-E3C6AF1802D9Q59268547-12040494-AFFA-4E79-A251-554000B37702Q67920934-1D209B36-3BBF-44A3-A9DF-B8AB3AEDE7A0Q68079666-B56C0F44-17BC-49CD-A869-CF4A7E24F24CQ68990174-A85EDB64-6A6B-425B-8B85-7A8FCAB54845Q70415474-2B8206A0-4F25-410C-82D5-EE39974F4D5FQ70472177-F5ACB827-FA6F-487D-85C6-DD55E43A0CA3Q70826101-10B7AFDF-10E5-4519-95B7-3C22E2B8C12DQ71185843-593565CF-9AA7-471C-90A3-4FD1C811E31EQ71477520-00A3082E-08B4-4BCC-A363-87499764EDB2Q71715354-96484465-3A3F-4B47-BE25-DB8E76309D57Q72326679-F23B932D-8743-4673-8759-7D659813C7CBQ73033828-C1B1FCC5-6402-4EE5-B507-62269E29BD0BQ73307391-6EB97D8A-68A4-4ABD-8FA9-50E7703C0D58Q73334322-EFF63F79-0473-42E2-A55A-FAD03C20A327Q73442739-BBF20012-FB3F-4949-9D6A-FFAD549AF840Q73762746-BD05F786-55BF-42EB-88E1-5ADCA5F05594
P50
description
researcher ORCID ID = 0000-0002-8432-7363
@en
wetenschapper
@nl
name
Bernard Le Bonniec
@ast
Bernard Le Bonniec
@en
Bernard Le Bonniec
@es
Bernard Le Bonniec
@nl
type
label
Bernard Le Bonniec
@ast
Bernard Le Bonniec
@en
Bernard Le Bonniec
@es
Bernard Le Bonniec
@nl
prefLabel
Bernard Le Bonniec
@ast
Bernard Le Bonniec
@en
Bernard Le Bonniec
@es
Bernard Le Bonniec
@nl
P106
P1153
7004224657
P31
P496
0000-0002-8432-7363